Abbvie

For more reports, please follow DrugTimes

If you are interested in similar assets, please contact DrugTimes BD Team at BD@drugtimes.cn asap. Many thanks!~

Drug discovery and development is not easy at all. We pay high respect to these heroes

Congratulations to Johnson & Johnson!

If you are looking for a promising TL1A product, please contact DrugTimes BD Team (BD@drugtimes.cn)

For more info, please visit https://www.drugtimes.cn/english-content

原文始发于微信公众号（药时代）：Semorinemab的失败，却重挫了Tau的希望？ 友情提醒：千人盛会将于11月4-5日在张江博雅酒店隆重召开。我们怀着激动的心情恭候已报名的嘉宾…

本文授权转载自生辉（ID：SciPhi）点击阅读原文 美国时间 7 月 27 日，阿斯利康与第一三共宣布达成合作，双方将共同开发第一三共开发的靶向人滋养层细胞表面糖蛋白抗原 2（T…